Cite

HARVARD Citation

    Lim, D. et al. (2021). Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab. Medical journal of Australia. 215 (9), p. 435. [Online]. 
  
Back to record